Securities Fraud Lawsuits Hit Endeavor, uniQure

The lawsuit against uniQure N.V. centers on its gene therapy candidate for Huntington's disease, AMT-130. The company is accused of making material misstatements and omissions regarding the therapy's clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA. Specifically, the complaint alleges that uniQure failed to disclose that the design of its pivotal study was not fully approved by the FDA. This includes the comparison of trial results to an external historical data set, a key part of their submission. Following uniQure's announcement on November 3, 2025, that the FDA no longer agreed the existing data was sufficient for a BLA submission, the company's stock price plummeted. Shares fell by as much as 66%, dropping from $67.69 to $34.29. The class period for the uniQure lawsuit covers investors who purchased shares between September 24, 2025, and October 31, 2025, with a lead plaintiff deadline of April 13, 2026. The Endeavor Group Holdings lawsuit is tied to its take-private merger. The complaint alleges that the company, its parent Silver Lake Group, and top executives worked to depress the value of shares for public shareholders. Investors accuse Endeavor of disseminating a misleading Information Statement on January 15, 2025. The lawsuit claims this document misrepresented the true value of the company's shares and failed to disclose conflicts of interest involving the special committee and its financial advisor. The suit alleges these actions were part of a scheme to lock in a $27.50 per share cash-out merger consideration, thereby harming minority shareholders while insiders benefited. The lead plaintiff deadline for sellers of Endeavor's Class A common stock between January 15, 2025, and March 24, 2025, is March 18, 2026.